Table 2.

Major clinical trials for management of advanced NETs

Study	Primary Endpoint	Study Population	Study Arms	Primary Endpoint Results	HR / P value
PROMID	PFS	Metastatic midgut NETs	Octreotide LAR 30 mg every 4 weeks vs. placebo	14.3 vs 6 months	HR, 0.34; P = 0.000072
CLARINET	PFS	Metastatic enteropancreatic NETs	Lanreotide 120 mg every 4 weeks vs. placebo	Median PFS not reached vs. 18 months	HR, 0.47; P < .001
RADIANT-4	PFS	Advanced nonfunctioning NETs of the lung or GI tract	Everolimus 10 mg daily vs placebo	11 vs 3.9 months	HR, 0.48; P < .00001
Sunitinib Malate	PFS	Advanced pancreatic NETs	Sunitinib 37.5 mg daily vs placebo	11.4 vs 5.5 months	HR, 0.42; P < .001
ECOG 2211	PFS	Advanced pancreatic NETs	Temozolomide vs. Temozolomide/Capecitabin e	14.4 vs. 22.7 months	HR, 0.58; P = .023
NETTER-1	PFS	Metastatic midgut NETs	177Lu-Dotatate q8 weeks plus best supportive care with ocreotide LAR vs. ocreotide LAR 60 mg every 4 weeks	Median PFS not reached vs 8.4 months	HR, 0.21; P < .0001